Searching... Searching...
  • NVP + NA
  • Köp NA
  • Sälj NA
  • Senast NA
  • SEK

  • NEVPF +NA
  • Buy NA
  • Sell NA
  • Latest NA
  • USD

Abliva completes the directed issue of MSEK 20 to Hadean Ventures

On April 22, 2020, the Board of Directors of Abliva AB (publ) ("Abliva" or the "Company") resolved, supported by the authorization granted at the Annual General Meeting on April 25, 2019, on a directed issue of up to 27,892,888 shares (the "Directed Issue") to Hadean Capital I AS and HVentures Capital I AB ("Hadean Ventures"). In connection with the resolution, Abliva and Hadean Ventures entered into an investment commitment of MSEK 20 that, among other things, regulates the subscription price in the Directed Issue. In accordance with the share issue resolution and the investment commitment, the subscription price shall be equal to the volume-weighted average price during the period 1 – 12 June 2020 ("VWAP"), however at maximum a of SEK 0.75.

The VWAP period has now ended and since the volume-weighted average price during the period well exceeds SEK 0.75, the Board has determined that the subscription price in the Directed Issue shall be SEK 0.75 per share. The Board has further decided to allocate a total of 26,666,666 shares to Hadean Ventures, of which Hadean Capital I AS has subscribed for, and been allotted, 18,345,570 shares and HVentures Capital I AB has subscribed for, and been allotted, 8,321,096 shares. Accordingly, the share capital will increase by SEK 1,333,333.30 to SEK 14,817,006.60. The dilution from the Directed Issue amounts to approximately 9 percent.

The purpose of the Directed Issue and the reason for deviation from the shareholders’ preferential rights is to broaden the Company’s ownership with an active and long-term investor, as well as to be able to carry out a capital raise in a timely and cost-effective manner.

Abliva will raise MSEK 20 before issue costs through the Directed Issue. The capital raised in the Directed Issue will be used to further advance the clinical development of KL1333, Abliva’s lead primary mitochondrial disease (PMD) project, and bring its second PMD project NV354 into clinical development.

Erik Penser Bank AB acts as financial advisor to Abliva in connection with the Directed Issue and Cirio Advokatbyrå AB acts as legal advisor.

For more information, please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@abliva.com


  • Press Releases

    Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures 08 October Abliva AB (Nasdaq Stockholm: ABLI) today announces that M... Read More